Home>>Signaling Pathways>> Immunology/Inflammation>> KEAP1-Nrf2>>Keap1-Nrf2-IN-1

Keap1-Nrf2-IN-1

Catalog No.GC36390

Keap1-Nrf2-IN-1 is a Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2) protein-protein interaction inhibitor, and with an IC50 of 43 nM for Keap1 protein.

Products are for research use only. Not for human use. We do not sell to patients.

Keap1-Nrf2-IN-1 Chemical Structure

Cas No.: 2232112-72-8

Size Price Stock Qty
100mg Please Inquire Please Inquire
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Keap1-Nrf2 IN-1 (compound35) is a Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (Keap1-Nrf2) protein-protein interaction inhibitor, and with an IC50 of 43 nM for Keap1 protein. Keap1-Nrf2 IN-1 (compound35) activates Nrf2-regulated cytoprotective response and antagonizes acetaminophen-induced liver injury both in cellular and in vivo models[1]. IC50: 43 nM (Keap1 protein)[1]

[1]. Lu MC, et al. Discovery of a Potent Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitor with Natural Proline Structure as a Cytoprotective Agent against Acetaminophen-Induced Hepatotoxicity. J Med Chem. 2019 Jul 25;62(14):6796-6813.

Reviews

Review for Keap1-Nrf2-IN-1

Average Rating: 5 ★★★★★ (Based on Reviews and 2 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Keap1-Nrf2-IN-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.